674 Topoisomerase II alpha (TOP2A) alterations as a predictive marker for epirubicin sensitivity in 805 high-risk breast cancer patients. A randomised DBCG trial (DBCG89D)
2003 ◽
Vol 1
(5)
◽
pp. S202-S203
◽
2011 ◽
Vol 126
(3)
◽
pp. 643-651
◽
2014 ◽
Vol 106
(5)
◽
2007 ◽
Vol 13
(10)
◽
pp. 2977-2985
◽
Keyword(s):
2002 ◽
Vol 11
(2)
◽
pp. 415-421
◽
Keyword(s):
2001 ◽
Vol 37
◽
pp. S173
◽
2018 ◽
Vol 143
(6)
◽
pp. 1416-1425
◽